AIMS: Clinicians need to get better at identifying patients who would have poor quality of anticoagulation control with vitamin-K antagonists (VKAs). We assessed the predictive ability of SAMe-TT2R2 score, recently conceived for the prior purpose, and examined its relationship with major bleeding, thromboembolic (TE) complications, and death. METHODS AND RESULTS: Retrospectively, 911 consecutive patients with non-valvular atrial fibrillation (NVAF) started on VKAs within 8 months were studied. The percentage of international normalized ratios in therapeutic range (PINRR) at different levels was used as a metric of anticoagulation quality. We also tested the SAMe-TT2R2 predictability for major bleeding, TE complications, and death throughout 10 ± 3 months. The PINRR decreased from 62% at zero point to 53% at ≥4 points of SAMe-TT2R2. 82.1% of patients who achieved PINRR ≥ 70% had 0 or 1 point of SAMe-TT2R2. SAMe-TT2R2 performed significantly better at PINRR 70% than at 65 and 60% (c-statistic = 0.60 vs. c-statistic = 0.56). The calibration of SAMe-TT2R2 was excellent (Hosmer-Lemeshow test P-values ≥ 0.6). SAMe-TT2R2 showed significant association with the composite outcome of major bleeding, TE complications, and death [n = 98; hazard ratio (HR) = 1.32; 95% confidence interval (CI) 1.08-1.60]; the c-statistic was 0.57 (95% CI: 0.51-0.62) and P = 0.03. As individual outcomes, SAMe-TT2R2 was significantly associated with death (n = 60; HR = 1.3; 95% CI: 1.03-1.69), but not with either major bleeding (n = 30; HR = 1.2; 95% CI: 0.85-1.76) or TE complications (n = 15; HR = 1.01; 95% CI: 0.58-1.77). CONCLUSION: Among NVAF patients, SAMe-TT2R2 could represent a useful clinical tool to identify patients who would have poor quality of anticoagulation control with VKAs. SAMe-TT2R2 successfully predicts the composite outcome of major bleeding, TE complications, and death. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Clinicians need to get better at identifying patients who would have poor quality of anticoagulation control with vitamin-K antagonists (VKAs). We assessed the predictive ability of SAMe-TT2R2 score, recently conceived for the prior purpose, and examined its relationship with major bleeding, thromboembolic (TE) complications, and death. METHODS AND RESULTS: Retrospectively, 911 consecutive patients with non-valvular atrial fibrillation (NVAF) started on VKAs within 8 months were studied. The percentage of international normalized ratios in therapeutic range (PINRR) at different levels was used as a metric of anticoagulation quality. We also tested the SAMe-TT2R2 predictability for major bleeding, TE complications, and death throughout 10 ± 3 months. The PINRR decreased from 62% at zero point to 53% at ≥4 points of SAMe-TT2R2. 82.1% of patients who achieved PINRR ≥ 70% had 0 or 1 point of SAMe-TT2R2. SAMe-TT2R2 performed significantly better at PINRR 70% than at 65 and 60% (c-statistic = 0.60 vs. c-statistic = 0.56). The calibration of SAMe-TT2R2 was excellent (Hosmer-Lemeshow test P-values ≥ 0.6). SAMe-TT2R2 showed significant association with the composite outcome of major bleeding, TE complications, and death [n = 98; hazard ratio (HR) = 1.32; 95% confidence interval (CI) 1.08-1.60]; the c-statistic was 0.57 (95% CI: 0.51-0.62) and P = 0.03. As individual outcomes, SAMe-TT2R2 was significantly associated with death (n = 60; HR = 1.3; 95% CI: 1.03-1.69), but not with either major bleeding (n = 30; HR = 1.2; 95% CI: 0.85-1.76) or TE complications (n = 15; HR = 1.01; 95% CI: 0.58-1.77). CONCLUSION: Among NVAF patients, SAMe-TT2R2 could represent a useful clinical tool to identify patients who would have poor quality of anticoagulation control with VKAs. SAMe-TT2R2 successfully predicts the composite outcome of major bleeding, TE complications, and death. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Akash Kataruka; Xiaowen Kong; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Gregory D Krol; Scott Kaatz; Michael W McNamara; James B Froehlich; Geoffrey D Barnes Journal: Vasc Med Date: 2017-02-01 Impact factor: 3.239
Authors: Darae Ko; Faisal Rahman; Maria A P Martins; Elaine M Hylek; Patrick T Ellinor; Renate B Schnabel; Emelia J Benjamin; Ingrid E Christophersen Journal: Nat Rev Cardiol Date: 2016-10-27 Impact factor: 32.419
Authors: Sylvia Haas; Hugo Ten Cate; Gabriele Accetta; Pantep Angchaisuksiri; Jean-Pierre Bassand; A John Camm; Ramon Corbalan; Harald Darius; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Barry Jacobson; Gloria Kayani; Lorenzo G Mantovani; Frank Misselwitz; Karen Pieper; Sebastian M Schellong; Janina Stepinska; Alexander G G Turpie; Martin van Eickels; Ajay K Kakkar Journal: PLoS One Date: 2016-10-28 Impact factor: 3.240
Authors: Samantha Wasniewski; Luciano Consuegra-Sánchez; Pablo Conesa-Zamora; Luis García de Guadiana-Romualdo; Pablo Ramos-Ruiz; Marta Merelo-Nicolás; F Guillermo Clavel-Ruipérez; Begoña Alburquerque-González; Federico Soria-Arcos; Juan A Castillo-Moreno Journal: Biomed Res Int Date: 2018-10-17 Impact factor: 3.411
Authors: Carlos Escobar; Xavier Borrás; Ramón Bover Freire; Carlos González-Juanatey; Miren Morillas; Alfonso Valle Muñoz; Juan José Gómez-Doblas Journal: PLoS One Date: 2020-06-01 Impact factor: 3.240
Authors: Hallie B Remer; Xiaokui Gu; Brian Haymart; Geoffrey D Barnes; Mona A Ali; Eva Kline-Rogers; Tina Alexandris-Souphis; Jay H Kozlowski; James B Froehlich; Vinay Shah; Gregory D Krol; Scott Kaatz Journal: Blood Adv Date: 2022-05-24